Business Monitor International


Biosimilar Opportunities in an Evolving Market

Published 19 August 2013

  • 126 pages
  • Instant access to your report in PDF format through your account library
 
$1,495.00
Biosimilar Opportunities in an Evolving Market

In terms of revenue, six of the top ten pharmaceutical therapies are biological products, which have been targeted by biosimilar developers: AbbVie's Humira (adalimumab), Roche's MabThera (rituxan), Herceptin (trastuzumab) and Avastin (bevacizumab), Sanofi's Lantus (insulin glargine), and Johnson & Johnson's Remicade (infliximab). These products had combined global sales of US$41.4 billion in

2012. Also of significant importance to biosimilar developers but just outside the top ten with sales of US$4.2 billion in 2012 is Amgen's Enbrei (etanercept).

The EU market is on the verge of a new generation of biosimilars, following announcements from Celltrion and Hospira at the end of June 2013 that the European Medicines Agency's Committee for Medical Products for Human Use has issued a positive opinion for the first biosimilar infliximab for the treatment of rheumatoid arthritis, inflammatory bowel disease and plaque psoriasis. Celltrion has already received market approval for its infliximab biosimilar in South Korea, under the brand name Remsima.Hospira intends to market the product as lnflectra, following final approval. lnflectra/Remsima is the first monoclonal antibody (mAb) therapy to reach a positive opinion following review via the EMA biosimilars regulatory pathway and represents an important milestone for a new era of lower-cost biological therapies in Europe.

Thus far, the biosimilar market has been largely reliant on three products: somatropin; erythropoietin, also known as epoetin or EPO; and human granulocyte colony stimulating factor (G-CSF, filgrastim). Numerous versions of these products are available in semi-regulated markets around the world. In the EU, fourteen biosimilar products currently have marketing authorisation. Other highly regulated markets with biosimilars approved include Australia, Canada and Japan. In the USA, the long drawn out process toward biosimilar regulation has kept this market out of reach. However, as US legislation comes into...

The long awaited promise of biosimilars takes another step to fulfilment with the first approval in Europe of high-value second generation products. But what products can be expected to follow, who is developing them and what are the hot prospects?

Biosimilars: another milestone passed

At the end of June 2013, the European Medicines Agency’s Committee for Medical Products for Human Use issued a positive opinion for the first biosimilar version of Johnson & Johnson’s infliximab for the treatment of rheumatoid arthritis, inflammatory bowel disease and plaque psoriasis. For the two successful applicants, Celltrion and Hospira, this development passes a significant milestone for the whole biosimilar sector as the products are the first monoclonal antibody (mAb) therapies to reach a positive opinion following review via the EMA biosimilars regulatory pathway. This is an important event which heralds a new era of lower-cost biological therapies in Europe.
For J&J and its partners, the news is less welcome. Already under pressure from branded competitors in the TNF inhibitor market, it is no surprise that both developer and biosimilar companies will be assessing what share they may secure of its US$6.13 billion revenues.

The tip of a US$41 billion iceberg

While significant for J&J, infliximab is just the tip of the iceberg when it comes to the potential for biosimilars. In terms of revenue, six of the top ten pharmaceutical therapies are biological products, which have been targeted by biosimilar developers: Abbvie’s Humira (adalimumab), Roche’s MabThera (rituximab), Herceptin (trastuzumab) and Avastin (bevacizumab), Sanofi’s Lantus (insulin glargine), and Johnson & Johnson’s Remicade (infliximab). These products had combined global sales of US$41.4 billion in 2012. Also
of significant importance to biosimilar developers, with sales of US$4.2 billion in 2012 is Amgen’s Enbrel (etanercept).

Open season: Branded industry gets in on the act

It may have taken a while, but the world’s major pharmaceutical originators have recognised the potential for biosimilars. A number have disclosed their intentions and/or announced clinical trials in recent months. For example, in February 2013, Amgen announced plans to launch a portfolio of six new biosimilars beginning in 2017: adalimumab, infliximab, bevacizumab, trastuzumab, rituximab and cetuximab. Four of these projects form part of the
company’s development agreement with Actavis. In June 2012, Merck KGaA and Dr Reddy's Laboratories announced a partnership to co-develop a portfolio of biosimilar compounds in oncology, primarily focused on monoclonal antibodies. Pfizer has been openly active in generics and biosimilars for some time. The company previously had a collaborative deal with Biocon for its insulin products, although this deal was concluded in March 2012. In May 2013, Pfizer began a Phase I trial with an infliximab biosimilar, PF-06438179. Many smaller biosimilar developers have the ambition but not the resources. The increasing interest from big Pharma will bring a welcome boost of expertise and funding to research and partnering.

The US Market: Not the elephant in the room

In any analysis of the pharma industry the US looms large – but not in biosimilars. The painfully slow progress to a regulatory pathway for biosimilars – still untried – has handed the initiative to others. The EU biosimilar regulations have been imitated widely in other countries, while the emphasis of biosimilar research sits firmly in Asia, notably India, China and South Korea. Of course, the big prize for all biosimilar manufacturers is the US market, which accounts for approximately 50% of the global value.

This report answers key questions:

  • Where is less competition to be found in the first phase of biosimilars in Epoetin and G-CSF?
  • Biosimilars are more widely available in emerging markets – what lessons can be learnt?
  • What are the latest State regulatory developments in the US and will they help or hinder?
  • Which are the companies to watch, and why?
  • Six companies are targeting Abbvie’s Humira, who are they and what is the status of their research?

 

Foreword & Executive Summary
• Biosimilars: What Are They and Why
Are We Interested?
• What Is A Biotech Drug?
• Biosimilars and Biobetters Defined
Product Analysis
Each product review which follows covers,
where appropriate,
• Developer/Background
• Mode of Action
• Approvals
• Competition within the Marketplace
• Patents
• Sales Trends
First Generation Biosimilars
Erythropoietin
• Epogen/Eprex/Procrit (epoetin alfa)
• Aranesp (darbepoetin alfa)
• NeoRecormon (epoetin beta)
• Mircera (methoxy polyethylene glycolepoetin
beta)
• Biosimilar Erythropoietin
- Europe
- USA
- Rest of the World (Epoetin &
Darbepoetin)
G-CSF
• Neupogen (filgrastim)
• Neulasta (pegfilgrastim)
• Neutrogin/Granocyte (lenograstim)
• Biosimilar G-CSF
- Europe (Filgrastim and
Pegfilgrastim)
- USA
- Rest of the World
Human Growth Hormone (Somatropin)
• Genotropin
• Humatrope
• Norditropin
• Nutropin
• Saizen
• Biosimilar Somatropin
- Europe
- USA
- Rest of the World
Follicle Stimulating Hormone
• Gonal-f (follitropin alfa)
• Biosimilar Follitropin Alfa
- Europe
- USA
- Rest of the World
Human Insulin
• Humulin (insulin [rDNA origin])
• Humalog (insulin lispro)
• Lantus (insulin glargine)
• Apidra (insulin glulisine)
• Levemir (insulin detemir)
• NovoRapid & NovoMix (insulin aspart)
• Biosimilar Human Insulin
- Europe and USA
- Rest of the World
Interferon
• PegIntron (peginterferon alfa-2b)
• Pegasys (pegylated-40K interferon
alfa-2a)
• Avonex (interferon beta-1a)
• Rebif (interferon beta-1a)
• Betaferon/Betaseron & Extavia
(interferon beta-1b)
• Biosimilar Interferon
- Europe
- Rest of the World
The Next Biosimilar Generation:
Etanercept and Monoclonal Antibodies
• Enbrel (etanercept)
• Biosimilar Etanercept
• Remicade (infliximab)
• Rituxan/MabThera (rituximab)
• Herceptin (trastuzumab)
• Humira (adalimumab)
• Avastin (bevacizumab)
• Erbitux (cetuximab)
Biosimilar mAb Development
• Adalimumab
• Bevacizumab
• Cetuximab
• Infliximab
• Rituximab
• Trastuzumab
• Multiple mAb Development
Agreements
- Oncobiologics Biosimilar
Collaborations
Biosimilar Regulation
• European Union
• United States
Regulation in Other Developed Markets
• Australia
• Canada
• Japan
• Singapore
Regulation in Emerging Markets
• Brazil
• India
• Malaysia
• Mexico
• Peru
• South Korea
• Turkey
The Key Players
• Sandoz
• Teva
• Hospira
Companies to Watch
• Actavis
• Biocon and Mylan
• Celltrion
• Ranbaxy
Major Pharma Companies – Recent
Developments
• Amgen
• Merck & Co and Samsung Bioepis
• Merck Serono and Dr Reddy’s
• Pfizer
• Sanofi
Company Directory
List of Tables
• Biosimilars Approved in the EU
• Five-year Sales of Leading EPO Brands (US$ M)
• Epogen US Patents
• Epogen/Eprex/Procrit Sales, 2003-2012 (US$ M)
• Aranesp US & EU Patents
• Aranesp Sales, 2003-2012 (US$ M)
• NeoRecormon/Epogin Sales, 2003-2012 (CHF & US$ M)
• Mircera Sales, 2003-2012 (CHF & US$ M)
• EU Marketing Authorisations for Biosimilar Eprex
• Biosimilar Epoetin in Emerging Markets
• Five-year Sales of Leading G-CSF Brands (US$ M)
• Filgrastim US Patents
• Neupogen Sales, 2003-2012 (US$ M)
• Pegfilgrastim Patents
• Neulasta Sales, 2003-2012 (US$ M)
• Neutrogin/Granocyte Sales, 2003-2012 (CHF & US$ M)
• EU Marketing Authorisations for Biosimilar Filgrastim
• Biosimilar G-CSF in Emerging Markets
• Five-year Sales of Leading Somatropin Brands (US$ M)
• Gentropin Sales, 2003-2012 (US$ M)
• Humatrope Sales, 2003-2012 (US$ M)
• Norditropin Sales, 2003-2012 (DKK & US$ M)
• Nutropin Sales, 2003-2012 (US$ M)
• Saizen Sales, 2003-2012 (EUR & US$ M)
• Biosimilar HGH in Emerging Markets
• Gonal-f US Patents
• Gonal-f Sales, 2003-2012 (EUR & US$ M)
• Biosimilar FSH in Emerging Markets
• Five-Year Sales of Leading Insulin Brands (US$ M)
• Humulin Sales, 2003-2012 (US$ M)
• Humalog US Patents
• Humalog Sales, 2003-2012 (US$ M)
• Lantus US Patents
• Lantus Sales, 2003-2012 (EUR & US$ M)
• Apidra US Patents
• Apidra Sales, 2008-2012 (EUR & US$ M)
• Levemir US Patents
• Levemir Sales, 2005-2012 (DKK & US$ M)
• NovoRapid & NovoMix US Patents
• NovoRapid & NovoMix Sales, 2005-2012 (DKK & US$ M)
• Five-year Sales of Leading Interferon Alfa Brands (US$ M)
• Five-year Sales of Leading Interferon Beta Brands (US$ M)
• PegIntron US Patents
• PegIntron Sales, 2003-2012 (US$ M)
• Pegasys US Patents
• Pegasys Sales, 2003-2012 (CHF & US$ M)
• Avonex US Patents
• Avonex Sales 2003-2012 (US$ M)
• Rebif Sales, 2003-2012 (EUR & US$ M)
• Betaferon/Betaseron & Extavia Sales, 2003-2012
(EUR & US$ M)
• Biosimilar Interferon in Emerging Markets
• Five-Year Sales of Enbrel and Leading Monoclonal
Antibodies (US$ M)
• Enbrel US Patents
• Enbrel Sales by Company, 2003-2012 (US$ M)
• Remicade US Patents
• Remicade Sales by Company, 2003-2012 (US$ M)
• Rituxan/MabThera Sales, 2003-2012 (CHF & US$ M)
• Herceptin US Patents
• Herceptin Sales, 2003-2012 (CHF & US$)
• Humira US Patents
• Humira Sales by Company, 2003-2012 (US$ M)
• Avastin Sales, 2004-2012 (CHF & US$ M)
• Erbitux Sales by Company, 2004-2012 (EUR & US$ M)

 

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%